| Literature DB >> 20972826 |
Marc Vanderheyden1, Chris Vrints, Jozef Bartunek.
Abstract
To date, cardiac resynchronization therapy remains the only treatment that enhances systolic function while improving long-term outcome and survival. Here, we review the molecular alterations associated with dyssynchronous heart failure and their reversibility induced by cardiac resynchronization therapy. We focus upon the molecular portrait of dyssynchronous heart failure and how cardiac resynchronization therapy influences electrophysiologic, metabolic and adrenergic pathways.Entities:
Mesh:
Substances:
Year: 2011 PMID: 20972826 DOI: 10.1007/s10741-010-9199-x
Source DB: PubMed Journal: Heart Fail Rev ISSN: 1382-4147 Impact factor: 4.214